CLXClorox
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $1.55Beat
- vs $0.97 expected on Nov 2
- Stock move on it
- +4.34%
- one session
- Typical move
- ±4.2%
- average over 2 reports
- Price
- $108.22
- +1.27% today · $12.0B cap
Past and upcoming reports
2
| Nov 2, 2026 | Sep 30, 2026 | Time not given | $0.97 | Beat$1.55 | +4.34% |
| Jul 30, 2026 | Jun 30, 2026 | Time not given | $1.66 | not recorded | −4.12%2d |
After the report
Jul 30, 2026 report
This covers the Jul 30, 2026 report. The Nov 2, 2026 numbers are in the table above.
Clorox Falls 1.2% on Revenue Decline, Cautious Outlook
Clorox reported fiscal Q4 results with revenue declining ~4% year-over-year, aligning with expectations for a weak quarter. Actual EPS was not disclosed. consensus was $1.66. The stock fell 1.2% with heavy volume, reflecting disappointment. Management struck a cautious tone, pointing to sustained category headwinds and cost pressures, reinforcing a deteriorating growth narrative.
Reported against expected
MissedConsensus EPS estimate was $1.66, but actual figures were not reported in this dataset. Price action (-1.2% on elevated volume of 3.13M shares) suggests the overall report fell short of expectations, driven by a 4.1% year-over-year revenue decline and cautious guidance.
Guidance
Management offered a cautious forward view, emphasizing continued revenue headwinds and cost pressures. The stock_intelligence label 'cautious' and 'growth outlook deteriorating significantly' confirm a negative guidance tone.
How the stock reacted
CLX fell 1.22% to $95.55 on July 31, the day after the report, with volume of 3.13 million shares (vs. average ~2M), confirming active selling. The stock remains below its 50-day SMA ($95.11) and well below its 200-day SMA ($104.59).
What changed
Revenue declined ~4% YoY. guidance points to further weakness.
What the price now assumes
Market repricing growth lower despite cheap 15.8x P/E, reflecting fear of persistent top line contraction.
What it means for the business
Downgrade bias: deteriorating top line challenges bull thesis. watch next quarter's revenue trajectory.
The next one to three months, as we saw it then
Better case20%
Demand stabilizes and cost savings improve margins, beating low expectations.
Base case50%
Revenue continues to decline ~4% YoY, stock range-bound between $90 and $100.
Worse case30%
Headwinds intensify, leading to further revenue erosion and potential dividend reduction.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.